|
English
|
正體中文
|
简体中文
|
總筆數 :0
|
|
造訪人次 :
52736605
線上人數 :
553
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
顯示項目 446361-446370 / 2348674 (共234868頁)
<< < 44632 44633 44634 44635 44636 44637 44638 44639 44640 44641 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C; Kuo S.-H; Hu F.-C; Cheng A.-L; Shih J.-Y; Yu C.-J; Chia-Chi Lin; Huang T.-C; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:37Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2018-09-10T06:52:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial
|
Chiun Hsu and Sung-Hsin Kuo and Fu-Chang Hu and Ann-Lii Cheng and Jin-Yuan Shih and Chong-Jen Yu and Chia-Chi Lin and Tsu-Chen Huang and Pan-Chyr Yang and Chih-Hsin Yang; Chong-Jen Yu; Sung-Hsin Kuo; JIN-YUAN SHIH; ANN-LII CHENG |
| 國家衛生研究院 |
2015-11 |
Gemcitabine synergistically enhances anti-tumor effects of recombinant immunogen-based cancer immunotherapy
|
Liu, SJ;Chang, LS;Yan, WL;Yeh, YC;Leng, CH |
| 國家衛生研究院 |
1997-05 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
|
Perng, RP; Chen, YM; MingLiu, J; Tsai, CM; Lin, WC; Yang, KY; WhangPeng, J |
| 臺大學術典藏 |
2021-02-23T08:26:35Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-12T04:01:31Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
YANG SHIH-HUNG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
顯示項目 446361-446370 / 2348674 (共234868頁)
<< < 44632 44633 44634 44635 44636 44637 44638 44639 44640 44641 > >>
每頁顯示[10|25|50]項目
|
